Highlighting the use of micro and nanoparticles based-drug delivery systems for the treatment of <i>Helicobacter pylori</i> infections

Souza, Maurício Palmeira Chaves de; Camargo, Bruna Almeida Furquim de; Spósito, Larissa; Fortunato, Giovanna Capaldi; Carvalho, Gabriela Corrêa; Marena, Gabriel Davi; Meneguin, Andréía Bagliotti; Bauab, Taís Maria; Chorilli, Marlus

doi:10.1080/1040841x.2021.1895721

Cited by 23 publications

(22 citation statements)

References 165 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since MNPs started to be synthesized, several reports have addressed the use of this type of nanomaterial in the controlled drug release field (Araujo et al, 2020, Araujo et al, 2020; Araújo et al, 2021; Souza et al, 2021). This is due to desirable characteristics such catalytic activity, UV photoactivity, reduced side effects, chemical stability, and easy functionalization (Baeza, Ruiz‐Molina, & Vallet‐Regí, 2017; Ghosh et al, 2008; Kamat, 2002; More et al, 2017; Paul & Sharma, 2010).…”

Section: Future Nanotechnological Therapies For Fungal Infectionmentioning

confidence: 99%

Natural product‐based nanomedicine applied to fungal infection treatment: A review of the last 4 years

Marena

Ramos

Carvalho

et al. 2022

Phytotherapy Research

Self Cite

View full text Add to dashboard Cite

Fungal infections are one of the main public health problems, especially in immunocompromised patients, nosocomial environments, patients with chronic diseases, and transplant recipients. These diseases are increasingly frequent and lethal because the microorganism has a high capacity to acquire resistance to available therapy. The main resistance factors are the emergence of new strains and the uncontrolled use of antifungals. It is, therefore, important to develop new methods that contribute to combating fungal diseases in the clinical area. Natural products have considerable potential for the development of new drugs with antifungal activity, mainly due to their biocompatibility and low toxic effect. This promising antimicrobial activity of natural products is mainly due to the presence of flavonoids, terpenes, and quinones, which explains their antifungal potential. Pharmaceutical nanotechnology has been explored to enhance the delivery, selectivity, and clinical efficacy of these products. Nanotechnological systems provide a safe and selective environment for various substances, such as natural products, improving antifungal activity. However, further safety experiments (in vivo or clinical trials) need to be carried out to prove the therapeutic action of natural products, since they may have undesirable, toxic, and mutagenic effects. Therefore, this review article addresses the main nanotechnological methods using natural products for effective future treatment against the main fungal diseases.

show abstract

Section: Future Nanotechnological Therapies For Fungal Infectionmentioning

confidence: 99%

Natural product‐based nanomedicine applied to fungal infection treatment: A review of the last 4 years

Marena

Ramos

Carvalho

et al. 2022

Phytotherapy Research

Self Cite

View full text Add to dashboard Cite

show abstract

“…In the current study, it was decided to use PA12 as an excipient for sintering matrix tablets containing Met. The study's goals were: (1) to present the proof of concept of obtaining a highly drug-loaded, polymer-reinforced composite formulation, using FDDS as a working example; (2) to evaluate the properties of nylon as an inert 3D SLS printable excipient for Met incorporation; (3) to investigate the extended in vitro drug release behavior and to assess possible degrees of freedom for dissolution tuning.…”

Section: Introductionmentioning

confidence: 99%

“…Application of Floating Drug Delivery Systems (FDDS) is the primary method of increasing gastric residence time [ 1 ]. Therefore, FDDS are suitable for the treatment of local Helicobacter pylori gastrointestinal infections [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

Development of Composite, Reinforced, Highly Drug-Loaded Pharmaceutical Printlets Manufactured by Selective Laser Sintering—In Search of Relevant Excipients for Pharmaceutical 3D Printing

et al. 2022

View full text Add to dashboard Cite

3D printing by selective laser sintering (SLS) of high-dose drug delivery systems using pure brittle crystalline active pharmaceutical ingredients (API) is possible but impractical. Currently used pharmaceutical grade excipients, including polymers, are primarily designed for powder compression, ensuring good mechanical properties. Using these excipients for SLS usually leads to poor mechanical properties of printed tablets (printlets). Composite printlets consisting of sintered carbon-stained polyamide (PA12) and metronidazole (Met) were manufactured by SLS to overcome the issue. The printlets were characterized using DSC and IR spectroscopy together with an assessment of mechanical properties. Functional properties of the printlets, i.e., drug release in USP3 and USP4 apparatus together with flotation assessment, were evaluated. The printlets contained 80 to 90% of Met (therapeutic dose ca. 600 mg), had hardness above 40 N (comparable with compressed tablets) and were of good quality with internal porous structure, which assured flotation. The thermal stability of the composite material and the identity of its constituents were confirmed. Elastic PA12 mesh maintained the shape and structure of the printlets during drug dissolution and flotation. Laser speed and the addition of an osmotic agent in low content influenced drug release virtually not changing composition of the printlet; time to release 80% of Met varied from 0.5 to 5 h. Composite printlets consisting of elastic insoluble PA12 mesh filled with high content of crystalline Met were manufactured by 3D SLS printing. Dissolution modification by the addition of an osmotic agent was demonstrated. The study shows the need to define the requirements for excipients dedicated to 3D printing and to search for appropriate materials for this purpose.

show abstract

“…Nanocarriers can improve drug bioavailability by protecting encapsulated drugs from the adverse gastric environment and facilitating penetration of the mucosal barrier, so that to efficiently deliver drugs to target sites. 3 , 8 These nanocarriers include nanostructured lipid carriers, liposomes, nanoemulsions, metallic nanoparticles, polymeric nanoparticles, and microtechnological systems. 8 Among them, liposomes are promising nanoparticles for the treatment of H. pylori infection because of their biocompatibility, highly efficient encapsulation of both hydrophilic and hydrophobic drugs, and drug protection in the gastric environment.…”

Section: Introductionmentioning

confidence: 99%

“… 3 , 8 These nanocarriers include nanostructured lipid carriers, liposomes, nanoemulsions, metallic nanoparticles, polymeric nanoparticles, and microtechnological systems. 8 Among them, liposomes are promising nanoparticles for the treatment of H. pylori infection because of their biocompatibility, highly efficient encapsulation of both hydrophilic and hydrophobic drugs, and drug protection in the gastric environment. 8 Moreover, liposomes have already been commercialized for medical applications.…”

Section: Introductionmentioning

confidence: 99%

Cosmetic-Derived Mannosylerythritol Lipid-B-Phospholipid Nanoliposome: An Acid-Stabilized Carrier for Efficient Gastromucosal Delivery of Amoxicillin for In Vivo Treatment of Helicobacter pylori

Geng

Cheng

et al. 2022

ACS Omega

View full text Add to dashboard Cite

Helicobacter pylori infection is a leading cause of gastritis and peptic ulcer. Current treatments for H. pylori are limited by the increase in antibiotic-resistant strains and low drug delivery to the infection site, indicating the need for effective delivery systems of antibiotics. Although liposomes are the most successful drug delivery carriers that have already been applied commercially, their acidic stability still stands as a problem. Herein, we developed a novel nanoliposome using cosmetic raw materials of mannosylerythritol lipid-B (MEL-B), soy bean lecithin, and cholesterol, namely, LipoSC-MELB. LipoSC-MELB exhibited enhanced stability under the simulated gastric-acid condition, owing to its strong intermolecular hydrogen-bond interactions caused by the incorporation of MEL-B. Moreover, amoxicillin-loaded LipoSC-MELB (LipoSC-MELB/AMX) had a particle size of approximately 100 nm and exhibited sustained drug release under varying pH conditions (pH 3–7). Besides, LipoSC-MELB/AMX exhibited significantly higher anti- H. pylori and anti- H. pylori biofilm activity as compared with free AMX. Furthermore, LipoSC-MELB was able to carry AMX across the barriers of gastric mucus and H. pylori biofilms. Remarkably, in vivo assays indicated that LipoSC-MELB/AMX was effective in treating H. pylori infection and its associated gastritis and gastric ulcers. Overall, the findings of this study showed that LipoSC-MELB was effective for gastromucosal delivery of amoxicillin to improve its bioavailability for the treatment of H. pylori infection.

show abstract

Highlighting the use of micro and nanoparticles based-drug delivery systems for the treatment of Helicobacter pylori infections

Cited by 23 publications

References 165 publications

Natural product‐based nanomedicine applied to fungal infection treatment: A review of the last 4 years

Natural product‐based nanomedicine applied to fungal infection treatment: A review of the last 4 years

Development of Composite, Reinforced, Highly Drug-Loaded Pharmaceutical Printlets Manufactured by Selective Laser Sintering—In Search of Relevant Excipients for Pharmaceutical 3D Printing

Cosmetic-Derived Mannosylerythritol Lipid-B-Phospholipid Nanoliposome: An Acid-Stabilized Carrier for Efficient Gastromucosal Delivery of Amoxicillin for In Vivo Treatment of Helicobacter pylori

Contact Info

Product

Resources

About